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ABSTRACT 
Bilateral limbal stem cell deficiency (LSCD) treatment requires the need to obtain allogenic limbal tissue for 
transplantation. Outcomes of different surgical techniques depend on multiple factors, including the underlying etiology, 
ocular surface, eyelid status and used surgical intervention. Some of the management options for bilateral LSCD include 
cadaveric, living related or living non-related conjunctival limbal allograft (CLAL), keratolimbal allograft (KLAL), allogenic 
cultured limbal epithelial transplantation (CLET) and allogenic simple limbal epithelial transplantation (SLET). Systemic 
immunosuppressive therapy plays a pivotal role in survival of transplanted tissue. The present review focuses on 
different systemic immunosuppression protocols for limbal allograft and allogenic limbal epithelial cell transplantation, 
with specific emphasis on different surgical techniques and their outcomes. We included all reports with details of 
different systemic immunosuppression protocols for limbal allograft and allogenic limbal epithelial cell transplantation. 
Oral cyclosporine A at different doses is the most commonly used immunosuppressive agent in limbal allograft and 
allogenic limbal epithelial cell transplantation. However, different studies using oral mycophenolate mofetil and 
tacrolimus also reported good results. In conclusion, systemic immunosuppression protocols for limbal allograft and 
allogenic limbal epithelial cell transplantation are not standardized. Further studies regarding different surgical 
techniques should assess outcomes and adverse effects of such protocols. 
KEY WORDS 
Limbal Stem Cell Deficiency; Limbal Allograft; Limbal Epithelial Cell; Immunosuppressive Therapy 
Copyright © 2020, Author(s). This is an open-access article distributed under the terms of the Creative Commons 
Attribution-Non Commercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which 
permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited. 
Correspondence to: Dr. Juan Carlos Serna Ojeda, Instituto Vision Laser, Vazquez del Mercado 101-104 Centro, Aguascalientes, 
Aguascalientes. Email: juanc.sernao@gmail.com 
How to cite this article: Serna-Ojeda JC, Basu S, Vazirani J, Garfias Y, Sangwan VS. Systemic Immunosuppression for Limbal Allograft and 
Allogenic Limbal Epithelial Cell Transplantation. Med Hypothesis Discov Innov Ophthalmol. 2020 Spring; 9(1): 23-32. 
INTRODUCTION
Limbal stem cells located at limbal epithelial crypts within 
the limbal palisades of Vogt, play a fundamental role in 
maintenance of the corneal epithelium through 
proliferation and migration of new cells [1]. Several diseases 
can cause limbal stem cell deficiency (LSCD), including 
chemical injuries, Steven-Johnson syndrome (SJS), vernal 
keratoconjunctivitis (VKC), ocular cicatricial pemphigoid 
(OCP), contact lens use, ocular surface tumors, congenital 
aniridia, etc. [2]. Clinical findings in LSCD include 
conjunctivalization of the cornea, vascularization, chronic 
and persistent inflammation, irregular epithelial surface and 
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recurring erosions with persistent epithelial defects and 
ulceration [3]. 
In comparison with unilateral LSCD, bilateral LSCD offers a 
bigger challenge for treatment, as there is no healthy limbus 
in either eye [4]. This creates the need to obtain allogenic 
limbal tissue for transplantation. Some of the management 
options for bilateral LSCD include cadaveric, living related or 
living non-related conjunctival limbal allograft (CLAL), 
keratolimbal allograft (KLAL), allogenic cultured limbal 
epithelial transplantation (CLET) and allogenic simple limbal 
epithelial transplantation (SLET) [4-6].  
Outcomes of these techniques depend on multiple factors, 
including the underlying etiology of LSCD, ocular surface, 
eyelid status and used surgical intervention [7, 8]. However, 
systemic immunosuppressive therapy plays a pivotal role in 
survival of transplanted tissue. Transplantation of an 
allogenic limbal graft to a densely-vascularized area 
containing a lot of Langerhans cells increases the risk of 
rejection [9, 10]. Different studies have used and optimized 
immunosuppressive protocols according to their 
experiences.  
The present review focused on different systemic 
immunosuppression protocols for limbal allograft and 
allogenic limbal epithelial cell transplantation, with specific 
emphasis on different surgical techniques and their 
reported outcomes. 
METHODS 
This was a review performed by searching the PubMed 
database in June 2017 using the following search words; 
stem cell transplantation, limbal stem cells, stem cell 
deficiency, ocular surface reconstruction, limbal allograft 
and allogenic limbal epithelial cell transplantation. The 
search was restricted to publications in English or 
publications with English abstracts from 1990 to 2017. 
Relevant articles found in the reference lists were also 
included. We included all reports with details of different 
systemic immunosuppression protocols for limbal allograft 
and allogenic limbal epithelial cell transplantation. 
 
RESULTS 
Conjunctival Limbal Allograft  
In both living-related and living-nonrelated CLAL, free grafts 
including limbal tissue are harvested from the healthy eye 
and transplanted to the diseased eye [11]. Being one of the 
first techniques to treat LSCD, immunosuppressive 
management for patients undergoing this procedure has 
also been evolved.  
Initial reports of CLAL for eyes with bilateral surface 
disorders without systemic immunosuppression reported 
25% rejection rates, specifically for incompatible or non-
available data regarding HLA donor-recipient pairs. Kwitko 
found that patients with favorable course were either HLA 
identical or haplo-identical (50% identity) with their donors, 
thereby proposing HLA-matched allogeneic 
transplantation as a promising method [12]. Another report 
declaring long-term results of HLA-matched living related-
CLAL in 39 eyes with bilateral ocular surface disease, 
showed that at one-year follow-up, visual acuity improved 
in 46.2%, with 48.7% achieving an ambulatory vision and in 
84.6% stabilization of the corneal surface occurred [13]. 
However, other authors evaluated the use of an initial high 
dose of intravenous methylprednisolone and oral 
prednisolone with systemic cyclosporine A administered at 
doses between 1.5 and 5 mg/kg/day and subsequent 
tapering to a maintenance dose for patients receiving 
transplantation of limbal tissue from a HLA-matched relative 
donor [14]. Results showed that 80% of patients had 
improvement of corneal epithelium and reduction of 
vascularization, suggesting that low-maintenance dose of 
cyclosporine is helpful in living related-CLAL [14].  
Oral cyclosporine has been used in different studies, with an 
initial dose of 3 to 5 mg/kg, sometimes targeting blood 
levels to 100 to 150 ng/mL, and tapering to 2 to 4 mg/kg 
[15-17]. However, a high failure rate achieved with this 
therapy in severe chemical burns and SJS for both 
compatible (80%) and non-compatible living related-CLAL 
(92.3%) [15, 16]. Underlying etiology in these patients was 
definitely important, with patients presenting with LSCD 
secondary to chemical burn or mustard gas keratopathy, 
having less failure rates; whilst for SJS patients, satisfactory 
ocular surface reconstruction was reported in only 20% of 
cases, attributed to a high rate of postoperative local 
complications like infection [15, 17, 18]. Thus, failure of 
transplant may be more related with the underlying 
indication, rather than just the immunosuppression 
protocol. On the other hand, positive results were reported 
in a pediatric patient with SJS with severe cicatricial disease 
and a totally keratinized ocular surface, with the use of 
systemic cyclosporine and living related-CLAL [19]. Also, 
higher doses up to 10 mg/kg of body weight in divided 
doses, with addition of diltiazem 90 mg as an adjunct to 
increase serum levels of cyclosporine have been used for 
the treatment before visual rehabilitation with penetrating 
keratoplasty [20].  
Different systemic protocols appeared, like the use of 
tacrolimus 4 mg twice daily and mycophenolate mofetil 1 g 
twice daily by tapering after 6 months for a patient with 
LSCD due to sclerokeratitis treated with living related-CLAL, 
showing improvement in visual acuity and a stable ocular 
surface on follow-up [21].  
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Keratolimbal Allograft  
KLAL involves transfer of conjunctival and limbal tissue from 
a cadaver donor eye to an eye with severe LSCD. This 
technique has become one of the most accepted operations 
to regenerate the ocular surface. Although transplantation 
of limbal tissue from living related donors with HLA-
matched recipients was attempted to avoid systemic 
immunosuppression, eventual recurrence of vascularization 
on long-term follow-up in the initially successful cases led to 
the adaptation of immunosuppressive protocols [22]. Use of 
adequate systemic medication is important, as results of 
allograft transplantation are worse than autografts in terms 
of both corneal epithelialization and corneal clarity [23].  
Oral cyclosporine A has also been used as systemic 
immunosuppressive therapy in most early studies regarding 
KLAL. This agent was used for unique or co-adjuvant 
therapy, or in response to a rejection episode [24]. Case-
series using cyclosporine A in loading doses and then 
gradually tapering reported restoration of a stable ocular 
surface and healing in 65% to 75% of patients with diverse 
LSCD etiologies [25, 26].  
Different dose regimens have been tested for systemic 
cyclosporine. Holland reported a high-dose protocol for 
patients with diverse etiologies of LSCD undergoing KLAL, 
using 5 to 7 mg/kg per day [27]. Another protocol used was 
starting with 5 to 10 mg/kg before surgery and then 
maintaining serum levels of 100 to 150 ng/mL for one 
month, decreasing the doses to less than 5 mg/kg if serum 
level was above 150 ng/mL, or when kidney or liver function 
test results were out of normal range. For patients having 
good acceptance for cyclosporine A, the serum levels were 
maintained between 30 and 100 ng/mL for more than six 
months [28, 29]. Evaluation in patients with SJS, OCP, 
chemical and thermal burns reported that 51% had corneal 
epithelialization and 60% improved two or more lines of 
visual acuity, having better results in patients with burns 
[29]. A study that used this initial high-dose 
immunosuppression for at least 6 months, and tapering 
after that until 1 year, reported only nausea and vomiting in 
few cases attributed to cyclosporine [30].  
Lower doses of oral cyclosporine A, at a dosage of 3 to 5 
mg/kg per body weight starting before or at the time of 
operation, and then tapering to 1 to 2 mg/kg in long-term 
follow-up, demonstrated an overall graft survival rate of 
54.4% at 1 year, 33.3% at 2 years and 27.3% at 3 years in 
one report, and a survival of ambulatory vision of 53.6% at 3 
years and 44.6% at 5 years in another study [31, 32]. 
However, the two groups reached different conclusions, 
with the first one finding no difference in KLAL survival 
between patients treated or not treated with long-term 
cyclosporine A. This is probably because they administered 
oral immunosuppression in the first years after treatment 
only to high-risk patients and after occurrence of acute 
allograft rejection [31]. The other group achieved a low 
survival rate and mycophenolate mofetil was added [32]. A 
study in a large cohort of KLAL patients evaluating clinical 
characteristics of immunologic reactions, found rejection of 
the limbal graft in 13% of patients using intravenous 
cyclosporine A 3 mg/kg starting one day before surgery and 
continuing for 1 week, followed by oral medication 5 mg/kg 
and maintained for several months [33]. They suggested 
reducing the initial dose to 2 mg/kg in patients aged 70 
years or older [34].  
A similar protocol was implemented in another study of 
KLAL with simultaneous PK by Shi et al. in 2008. They 
administered oral cyclosporine A 3 to 4 mg/kg daily for 6 
months and tapered to 2 to 3 mg/kg daily for at least 1 year. 
This study showed limbal stem cell rejection at one year in 
39% (9/23 patients), and final survival of 87%, compared 
with 74% KLAL survival from other trials evaluating 
simultaneous procedures [32, 35]. However, corneal graft 
survival rates differed in the two studies, reported to be 
56.5% at a mean follow-up of 32 months, and 13.7% at 36 
months, respectively [32, 35]. This was probably due to 
differences in surgical indications and exclusion criteria. 
With similar doses of systemic cyclosporine, Shimazaki and 
coworkers found 35.5% of endothelial rejection in patients 
with simultaneous KLAL and PK [36].  
Other immunosuppressive drugs reported in limbal 
transplants include tacrolimus FK506, as a more potent 
immunosuppressant analog to cyclosporine A. Short-term 
success with use of tacrolimus in KLAL in six patients with 
LSCD has been reported [37]. Azathioprine 100 mg/day in 
addition to cyclosporine for patients with SJS or aniridic 
keratopathy has also been used [38, 39].  
The Cincinnati Eye Institute and University of Cincinnati 
described a systemic immunosuppression protocol 
addressing limbal transplantation with an approach similar 
to solid organ transplantation. They used high-dose oral 
corticosteroids, in addition to oral tacrolimus initiated at 4 
mg twice daily tapered after 6 months and oral 
mycophenolate mofetil 1 g twice daily tapered after 12 
months, depending on the results of the ocular surface [10]. 
Patients were also followed by a renal transplantation team. 
They added valganciclovir for prophylaxis against 
cytomegalovirus and trimethoprim/sulfamethoxazole for 
pneumocystis carinii [10]. 
This same immunosuppressive therapy was used in 
different studies to treat patients with LSCD secondary to 
soft contact lens wear and to methamphetamine 
production–related ocular injuries, with a high rate of 
symptom resolution, improvement in best-corrected visual 
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acuity (BCVA) and ocular surface stabilization in the first 
group, but a more challenging prognosis in the second 
because of severe inflammation, accompanying eye 
comorbidities and psychological treatment [40, 41]. 
In Cincinnati study, the incidence of rejection was 31.1% in a 
mean follow-up of 62.7 months, which was lower to other 
studies using only oral cyclosporine, compared to adding 
systemic tacrolimus and mycophenolate mofetil [42]. They 
also compared their results with a smaller series of 12 eyes 
by Liang and coworkers, finding rejection in only 16.7% over 
a mean follow-up of 61.2 months. In this study, patients 
received 1 gram of oral mycophenolate mofetil and 1 mg of 
tacrolimus two times a day starting before surgery. The 
doses were adjusted according to response of the ocular 
surface and systemic adverse effects. The doses were 
tapered to 0.5 gram (mycophenolate mofetil) and 0.25 
mg/kg (tacrolimus) per day and discontinued in case of graft 
failure or adverse effects [43].  
A group from Iran used cyclosporine A 5 mg/kg daily, then 
decreased to 3 mg/kg daily after some weeks and 
discontinued after 1.5 to 2 years, with mycophenolate 
mofetil 1 g two times a day started after surgery and 
continued for minimum 6 months in a group of patients 
undergoing KLAL in mustard gas-induced LSCD [44, 45]. The 
authors reported an acute rejection in 10% (4 of 40 eyes), 
resulting in only 4% graft failure (1 of 40 eyes), but with 3 
eyes requiring a repeated KLAL because of a recurrence of 
primary disease for a mean follow-up of 19.6 months [45]. 
Also, when combining KLAL before or concomitantly with 
lamellar keratoplasty, KLAL survival was about 84.4% with 
improvement in corneal surface in a mean follow-up of 41.4 
months [44]. 
The Cincinnati Procedure assessed living related CLAL and 
KLAL in eyes with severe bilateral ocular surface failure and 
conjunctival deficiency [46]. They evaluated 24 with the 
most common etiology of SJS who were followed for more 
than a year. They reported stabilization in the ocular surface 
in 54.2%, improving in 33.3%, and failing in 12.5% of eyes, 
with almost 80% of patients requiring a subsequent 
keratoplasty. [46] Later, the same group reported the 
Modified Cincinnati Procedure, which is a combination of 
conjunctival limbal autografts (CLAU) and KLAL for unilateral 
severe ocular surface disease, in a case series from patients 
with chemical burns, reporting that 73% had BCVA of 20/80 
or better, and ocular surface stability in 82% [47]. 
Oral mycophenolate mofetil 1 gram twice a day has also 
been indicated only in cases of acute rejection or adverse 
events of cyclosporine A [48]. Other immunosuppressive 
medications have been used. A case report described the 
use of intravenous immunoglobulin in a patient with 
antibody-mediated KLAL rejection resistant to systemic and 
topical corticosteroids, with an improvement in clinical signs 
and symptoms [49]. 
An important consideration in combination of different 
systemic medications is the possibility of adverse events. 
These include alterations in blood tests such as anemia, 
hyperglycemia, elevated creatinine and elevated liver 
function tests, which are usually normalized by decrease in 
doses or discontinuation of the medication [50]. In their 10-
year experience with this protocol, the group from 
Cincinnati reported severe adverse events (cardiovascular 
events) in only 1.5% of patients, and minor adverse events 
(transient biochemical abnormalities, increased 
cardiovascular risk, among others) in 14% of patients [10]. 
Also, even with the combination of medications, acute and 
chronic rejections remain an important issue among the 
complications on KLAL, and they may appear even as a late 
presentation [51, 52].  
Allogenic Cultured Limbal Epithelial Transplantation  
Evolution of tissue engineering for reconstruction of the 
ocular surface in bilateral LSCD allowed creation of an 
allogeneic corneal epithelial stem cell sheet. However, most 
allogeneic corneal epithelial transplantation usually fails 
without immunosuppressive therapy [53]. This usually 
occurs because allogeneic cultivated limbal cells can be 
target of immunological reactions, even if there are no 
antigen-presenting cells in the cultivated epithelial sheets 
[54]. Although a meta-analysis for ex vivo CLET showed no 
difference in success rate and visual acuity compared with 
autograft, immunosuppression is critical to the success of 
allogeneic grafts [55].  
Systemic cyclosporine A is also a common therapy in 
allogeneic CLET, but dosage and duration of treatment are 
not well-known [56]. In a case-series of ex-vivo expanded 
cultured corneal epithelial stem cells on a modified amniotic 
membrane surface, Schwab reported a successful outcome 
defined as restoration or improvement of vision, along with 
maintenance of corneal surface stability in 4 allogenic 
transplants treated with cyclosporine A 200 mg daily for 
immunosuppression, in a follow-up of 6 to 19 months [57, 
58]. However, cyclosporine A was early decreased or 
discontinued in all the patients, in one after 3 weeks due to 
a bacterial keratitis, in another after a subsequent ocular 
surgery 1 month later, and in 2 due to renal complications 
[58]. Therefore, subsequent studies attempted to reduce 
the doses of systemic immunosuppression. Daya et al. used 
3 mg/kg tapered to 2 mg/kg after 2 weeks, and then 
maintained indefinitely in a mean follow-up of 28 months 
for ex vivo expanded stem cell allografts, showing overall 
improvement in 70% of patients, and visual acuity 
improvement in 40% [59]. Shimazaki and coworkers used 
the same initial dose of 3 mg/kg systemic cyclosporine A, 
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continued for minimum of 6 months, with systemic levels 
maintained at 100 to 150 ng/mL, or blood cyclosporine 
levels of 800 to 1000 ng/mL after 2 hours [60-63]. In a study 
of thirteen eyes with severe limbal deficiency due to SJS, 
OCP and chemical burns, the epithelium regenerated and 
covered the ocular surface in 61.5% of eyes, but only 46.2% 
maintained the same result at last follow-up visits [60]. In an 
extended case series, they reported a poorer outcome, with 
most patients (7 of 12) in the allogenic group failing to 
achieve corneal epithelization [61]. 
With similar cyclosporine doses of 2 to 5 mg/kg/day, but 
maintained for 6 months and then tapered until it was 
stopped after the first year, Prabhasawat and coworkers 
found a high rate of success (85.7%, 6/7 eyes) with stable 
epithelialization in allograft cases, more commonly with 
LSCD due to chemical burns [64]. More recently, Shortt et al. 
assessed a daily dose of oral cyclosporine A 3.5 mg/kg 
continued for 6 months in patients with LSCD, showing 
improvement in the clinical parameters and visual acuity, 
restoration of a normal corneal phenotype, and appearance 
of normal confocal microscopy in 71% of allografts [65].  
Zakaria and coworkers, prescribed oral cyclosporine A 2 x 
125 mg/day for a similar duration of time, tapered with later 
discontinuation at one-year after transplant in 3 allogenic 
transplant recipients, and two achieved reversion to a 
persistent intact epithelium and a functional improvement 
[66]. 
Some studies added systemic cyclophosphamide due to its 
fast-acting effect, to prevent postoperative inflammation 
and rejection. Koizumi and coworkers used cyclosporine 
(150 mg/day) and cyclophosphamide (100 mg/day) in 
addition to oral corticosteroid, stopping the last two 1 to 2 
months after surgery, but continuing a low-dose 
cyclosporine (25–50 mg/day) for 6 months [67, 68]. With 
cultivated corneal epithelial transplantation to treat patients 
with severe LSCD of diverse etiologies, including acute and 
chronic SJS, acute and chronic chemical injuries, OCP and 
drug-induced pseudopemphigoid, the authors reported 
improvement in visual acuity in all eyes after surgery. In this 
study, 10 of 13 eyes improved two or more lines 6 months 
after the operation and 3 patients developed epithelial 
rejection during the follow-up period [67].  
The same group using autologous serum derived cultivated 
corneal epithelial transplantation for the treatment of 
severe ocular surface disease of diverse etiologies, used 
lower doses of immunosuppressive drugs, with oral 
cyclophosphamide (50 mg/day) and cyclosporine (100 
mg/day), discontinuing both medications between 1 and 3 
months after surgery, and reported that during the follow-
up period, the corneal surface of all patients remained 
stable [69]. With this protocol, those authors confirmed 
later that the allogeneic transplanted cells survived longer 
on the corneal surface maintaining ocular surface integrity, 
with the evaluation of two excised grafts of patients, 42 and 
75 months, respectively, after the initial graft 
transplantation [70].  
In the series of patients with allogeneic transplantation of 
cultivated limbal epithelium treated by Pauklin and 
coworkers, they also used 360 to 720 mg mycophenolate 
mofetil twice per day for 18 months in one patient because 
the original immunosuppressive therapy was not tolerated, 
unlike other patients who were treated with cyclosporine A 
100 mg twice per day for 12 to 15 months [71]. They 
reported a significant increase in visual acuity, and a stable 
central corneal surface restoration in 71.4% of eyes treated 
by allogeneic transplantation [71]. 
Allogenic Simple Limbal Epithelial Transplantation  
SLET is a recently reported technique in which a 2x2 mm 
strip of donor limbal tissue is obtained from the healthy eye 
and divided into eight to ten small pieces to distribute them 
over an amniotic membrane placed on the cornea of the 
recipient eye [72]. Long-term results in the treatment for 
unilateral cases of chemical burns have shown promising 
outcomes; however, no studies have evaluated its 
application to bilateral cases, were an allogenic limbal tissue 
is taken and harvested in the recipient cornea and using 
immunosuppressive therapy to increase the survival of 
limbal cells [73].  
A case report about a patient with bilateral total LSCD after 
a chemical injury and treated with allogenic SLET and 
postoperative management of topical and oral 
corticosteroids, reported an episode of acute rejection, 
managed with a single pulse dose of 500 mg intravenous 
methylprednisolone and hourly topical prednisolone 
acetate 1% eye drops, and then continued with tapering 
doses of oral prednisolone without additional 
immunosuppressive drugs [74]. A study evaluated the 
results of allogenic SLET without additional systemic 
immunosuppression in patients with acute severe chemical 
injuries, to achieve rapid epithelialization and prevent 
adverse effects of delayed epithelial healing; these patients 
achieved faster epithelialization, and only 5% required a 
subsequent lamellar keratoplasty [75]. Further studies in 
allogenic SLET may also address the results of systemic 
immunosuppression protocols. 
CONCLUSION 
Evaluating different systemic immunosuppression protocols 
for limbal allograft and allogenic limbal epithelial cell 
transplantation is difficult due to a wide diversity of 
variables including number of patients, etiology of LSCD, 
surgical technique, previous or concomitant ocular 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2020; 9(1)  
28 SYSTEMIC IMMUNOSUPPRESSION FOR LIMBAL ALLOGRAFT TRANSPLANTATION 
surgeries, follow-up time and outcome definitions. Table 1 
compares the outcomes of some of the published large 
studies (>35 eyes) that include systemic 
immunosuppression regimen and their outcomes. 
Oral cyclosporine A at different regimens is the most 
commonly used immunosuppressive agent in limbal 
allograft and allogenic limbal epithelial cell 
transplantation. However, different studies using oral 
mycophenolate mofetil and tacrolimus also reported 
good results. Further studies of different surgical 
techniques should assess outcomes and adverse effects 
of such protocols.  
 
Table 1: Published Large (>35 eyes) Studies of Limbal Allograft and Allogenic Limbal Epithelial Cell Transplantation With Systemic Immunosuppression Regimen. 
Author Year Surgical 
Technique 
Systemic 
immunosuppression 
protocols  
Details, causes of LSCD Eyes; n Mean follow-up Outcomes 
Tsubota et 
al [29] 
1999 Ring-shaped 
limbal tissue with 
epithelial stem 
cells, multiple 
surgeries in some 
cases) 
Oral cyclosporine A 
5 to 10 mg/kg of 
body weight and 
tapered. 
 
Severe ocular-
surface disorders, Stevens-
Johnson syndrome 
and ocular pemphigoid 
most common.  
43 Mean of 1163 days  
 
51 % 
had corneal epithelialization, 
of which 35% with clear 
cornea. 
Solomon et 
al [32] 
2002 KLAL+ AMT, in 
58.9% 
simultaneous PKP. 
Oral cyclosporine A 
5 mg/kg of body 
weight and tapered. 
Retrospective study of 
Patients with LSCD, most 
common cause was 
chemical burns. 
39 Mean follow-up was 
34.0 months (range, 
12 to 117.6) 
Survival of KLAL: 76.9% at 1 
year, 47.4% at 3 years, and 
23.7% at 5 years. Survival of 
PKP: 47.8% at 1 year. 
Maruyama-
Hosoi et al 
[33] 
2006 KLAL Intravenous 
cyclosporine A 3 
mg/kg starting 1 day 
before 
surgery and 
continuing for 1 
week, followed by 
oral cyclosporine 5 
mg/kg. 
Retrospective study to 
analyze characteristics of 
immunologic reactions. 
Stevens-Johnson syndrome 
and ocular cicatricial 
pemphigoid were the most 
common ones. 
85 Average follow-up 
was 46.6 months. 
 
55.3% had clear grafts at last 
examination.  
 
Javadi et al 
[45] 
2011 lr-CLAL and KLAL Oral cyclosporine A 
5 mg/kg of body 
weight daily and 
then reduced to 3 
mg/kg daily after 6 
months.  
Retrospective study of 
patients with delayed-onset 
mustard gas keratitis with 
simultaneous or subsequent 
corneal transplantation.  
72 Mean follow-up 
after lr-CLAL was 
65.6 months (range, 
30 to 102) and 19.6 
months (range, 13 to 
61) after KLAL.  
25% in the lr-CLAL required 
KLAL. The rejection-free graft 
survival rate  
was 52.2% in  
lr-CLAL and 80.7% in KLAL at 
month 10. 
Holland et 
al [10] 
2012 Most common 
KLAL (83.8%) 
Most common 
tacrolimus, 
mycophenolate 
mofetil, and 
prednisone (75%) 
 
Retrospective study of 
patients undergoing ocular 
surface stem cell 
transplantation 
225 Mean 53.9 months 
(range, 
3.6 to 147.3 
months). 
77.2% had a stable ocular 
surface. 
 
Ang et al 
[42] 
2013 Most common 
KLAL (80.6%) 
Oral prednisone, 
tacrolimus and 
mycophenolate 
mofetil 
 
Retrospective study to 
analyze ocular surface stem 
cell transplantation 
rejection. Aniridia most 
common indication. 
222 Mean follow-up of 
62.7 months (range, 
12.0 to  
158.3 month) 
Rejection occurred in 31.1% 
eyes; severe rejection 
in 19.4% and low-grade 
rejection in 11.7%. 
Baradaran-
Rafii et al 
[51] 
2013 KLAL 1 g of oral 
mycophenolate 
mofetil and 4 mg of 
tacrolimus twice a 
day starting 1 week 
preoperatively and 
tapered after 12 
months.  
Retrospective review of 
complications of KLAL in 
different etiologies of LSCD, 
more common chemical 
injuries.  
45 Mean follow-up time 
was 26.1  
months (range, 6 to 
48 months). 
At last 
follow-up, 73.4% had a stable 
ocular 
surface. 
Parihar et 
al [30] 
2017 Allogenic ex 
vivo cultivated 
LSCT (25 eyes) vs 
KLAL (25 eyes) 
Oral cyclosporine A 
5 to 10 mg/kg of 
body weight and 
tapered. 
Chemical / thermal burns 
injuries most common 
etiology in both groups 
50 1 year of follow-up Absence of conjunctival 
revascularization (LSCT: 
60%; KLAL: 54.54%)  
comparable in both groups. 
Abbreviations: AMT: Amniotic membrane transplantation.  KLAL: keratolimbal allograft. lr-CLAL: living-related conjunctival limbal allografts. LSCD: 
Limbal stem cell deficiency. LSCT: Limbal stem cell transplantation. PKP: Penetrating keratoplasty; n: number; %: percentage; mg/kg: milligrams per 
kilogram of body weight; vs: versus; g: gram; mg: milligrams.  
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